Diagnosis of leukocyte-mediated disease and halogen gas exposure
US10983137B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Jan 19, 2016 |
| Grant date | Apr 20, 2021 |
| Priority date | — |
| Expiry date | Oct 21, 2037 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/42
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
Described are glutathione adducts of fatty aldehydes (FALD-GSH) and methods useful in the detection of FALD-GSH in the identification of pathologies associated with leukocyte-mediated disease conditions, including eosinophil and neutrophil activation. Thus, the present disclosure provides methods of diagnosing a subject as having or being at risk of developing a leukocyte-mediated disease (LMD) comprising (a) detecting the level of glutathione adducts of 2-halofatty aldehydes (FALD-GSH) in a sample; (b) comparing the amount of FALD-GSH with a control or standard reflective of diseased and/or healthy levels of FALD-GSH; and (c) diagnosing the subject as having or being at risk of developing LMD if the level of FALD-GSH in the sample is higher than the control or standard.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.